EMD Serono, known as Merck KGaA outside of North America, has finish negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) that oversees new drugs coming in, and signed a letter of intent to an agreement that will allow Mavenclad to be available at low or no cost through the country’s publicly supported health programs.
Details on the financial arrangements were not disclosed.
This signing brings the two parties closer to bringing Mavenclad, a short-course and oral disease-modifying treatment, to eligible people across Canada, which has the world’s highest MS rate. Currently, the treatment is reimbursed to patients using private health insurance plans.
Company officials can now begin to work with agencies in each of the country’s 10 provinces and three northern territories for public funding of Mavenclad.
“We’re excited to complete the pCPA negotiations and reach an agreement on the terms of public reimbursement for Mavenclad,” Gaby Murphy, president & managing director at EMD Serono, Canada, said in a press release.
“We look forward to working with participating jurisdictions to achieve the timely listing of Mavenclad by their respective public drug plans, and ensure broader access to this treatment option for Canadians living with MS,” Murphy added.
Mavenclad was approved by Health Canada to reduce the frequency of MS flares and delay disease progression in adults with RRMS in November 2017. It is recommended for patients who had not an adequate response to, or cannot tolerate, one or more other approved MS therapies.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?